menu
    • menu
    [{"orgOrder":0,"company":"PCI Pharma Services","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Lenzilumab","moa":"||Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PCI Pharma Services","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PCI Pharma Services \/ PCI Pharma Services","highestDevelopmentStatusID":"10","companyTruncated":"PCI Pharma Services \/ PCI Pharma Services"}]

    Find Clinical Drug Pipeline Developments & Deals by PCI Pharma Services

    Menu

    PCI Pharma Services

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PCI Pharma Services

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            PCI Pharma Services

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lenzilumab,Remdesivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Humanigen

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the ...

                            Details : Under the agreement, PCI will purchase Humaneered (lenzilumab), for resale and distribution in the event a Conditional Marketing Authorization is received in the UK for use in patients hospitalized with COVID-19.

                            Product Name : Humaneered

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            June 16, 2022

                            Lead Product(s) : Lenzilumab,Remdesivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Humanigen

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth